Table 1

Summary of LAG-3-targeted drugs under clinical trial

NameDescriptionTarget diseaseClinical trial*Combination†
RelatlimabAntagonistic AbTumorsI (5), I/II (6), II (13)PD-1
LAG525Antagonistic AbTumorsI (1), I/II (1), II (3)PD-1, M-CSF, IL-1β, A2AR
BI754111Antagonistic AbTumorsI (3), Ia/Ib (1), II (1)PD-1
MK-4280Antagonistic AbTumorsI (1), I/II (1), II (1)PD-1
Sym022Antagonistic AbTumorsI (2)PD-1
TSR-033Antagonistic AbTumorsI (2)PD-1, Tim3
REGN3767Antagonistic AbTumorsI (1), II (1)PD-1
INCAGN2385-101Antagonistic AbTumorsI (1)
MGD013Bispecific to LAG-3/PD-1TumorsI (2), I/II (1), II/III (1)
FS118Bispecific to LAG-3/PD-L1TumorsI (1)
XmAb22841Bispecific to LAG-3/CTLA-4TumorsI (1)PD-1
GSK2831781Depleting AbAutoimmune diseasesI (2), II (1)
IMP321Soluble LAG-3-IgTumorsI (8), II (2)PD-1, PD-L1, vaccination
  • *The phase and the number of clinical trials listed on ClinicalTrials.gov are shown.

  • †Immune-related molecules targeted in combination therapies listed on ClinicalTrials.gov are shown.

  • A2AR, adenosine A2a receptor; CTLA-4, cytotoxic T lymphocyte antigen 4; IL-1β, interleukin 1b; M-CSF, macrophage colony stimulating factor; PD-1, programmed cell death 1; PD-L1, PD-1 ligand 1; Tim3, T-cell immunoglobulin and mucin-domain containing-3.